Prof Fuyuhiko Motoi, MD, PhD is an expert in Oncology at Yamagata University Hospital (Japan). As of November 2026, ScienceLeadR ranks Fuyuhiko Motoi in the top 1% of experts worldwide for Pancreatic Neoplasms, Pancreatic Diseases and Endocrine Gland Neoplasms. Fuyuhiko Motoi has authored 414 publications, the most recent in 2026. SLR score: 962 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Fuyuhiko Motoi, MD, PhD Yamagata University Hospital Japan
962 ScienceLeadR Reputation 962
Network Map

Oncology

Subspecialties: Surgery - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Yamagata University

2020 - 2026

Yamagata University Hospital

2021 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 414

Citations

Citations: 9 445 1st author: 25 Last author: 23 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prospective Evidence of Concomitant Pancreatic Ductal Adenocarcinoma Risk Among Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms Without Worrisome Features/High-risk Stigmata at Baseline.
PMID 43040604 — incidence, neoplasms, adenocarcinoma, cysts, history, general surgery
Ann Surg20260
Clinicopathological and prognostic features of pancreatic acinar cell carcinoma: a nationwide multicenter study in Japan.
PMID 43033256 — cells, acinar cells, absenteeism, therapeutics, gastrointestinal diseases, carcinoma, acinar cell, prognosis
J Gastroenterol20260
Identification of Candidate Partner Cells in Tumor-Stromal Interactions by Histology-Based Spatial Analysis for Prognostic Stratification After Neoadjuvant Chemotherapy.
PMID 43026772 — cells, neoplasms, drug therapy, histology, spatial analysis, chemotherapy
Cancers (Basel)20260
ASO Visual Abstract: Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy.
PMID 42995363 — pancreatic neoplasms, neoplasms, laparoscopy, neoplasm metastasis
Ann Surg Oncol20260
Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer.
PMID 42234435 — research design, pancreatic neoplasms, surgical procedures, operative, neoplasms, cohort studies, biomarkers, neoadjuvant therapy, therapeutics, carbohydrates
JAMA Surg20260

LeadR Networks

Main global connection map